Janus Henderson Group PLC Alx Oncology Holdings Inc Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$13.65 - $22.06 $12.5 Million - $20.3 Million	-918,908 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$21.49 - $74.4 $2.29 Million - $7.92 Million	-106,491 Reduced 10.39%	918,908 $19.8 Million
Q3 2021 Nov 16, 2021	SELL	$52.51 - $80.91 $10.4 Million - $16 Million	-198,214 Reduced 16.2%	1,025,399 $75.7 Million
Q2 2021 Aug 16, 2021	SELL	$52.2 - $75.23 $7.74 Million - $11.2 Million	-148,263 Reduced 10.81%	1,223,613 $66.9 Million
Q1 2021 May 17, 2021	SELL	$62.84 - $87.68 $16.1 Million - $22.5 Million	-256,323 Reduced 15.74%	1,371,876 $97.5 Million
Q4 2020 Feb 16, 2021	BUY	$34.11 - $112.26 $40.9 Million - $135 Million	1,198,397 Added 278.83%	1,628,199 $136 Million
Q3 2020 Nov 16, 2020	BUY	$29.36 - $47.1 $12.6 Million - $20.2 Million	429,802 New	429,802 $16.2 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $68.9M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.